Systemic augmentation of αB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 32, 2011, Pages 13287-13292

  Arac, Ahmet ^a   Brownell, Sara E ^a   Rothbard, Jonathan B ^a   Chen, Charlene ^a   Ko, Rose M ^a   Pereira, Marta P ^a   Albers, Gregory W ^a   Steinman, Lawrence ^a   Steinberg, Gary K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune system; Ischemic stroke

Indexed keywords

ALPHA CRYSTALLIN; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; HEART STROKE VOLUME; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE; WILD TYPE; ANIMAL; BLOOD; BRAIN; DRUG EFFECT; IMMUNOLOGY; PATHOLOGY; T LYMPHOCYTE; TIME;

MUS;

ALPHA-CRYSTALLIN B CHAIN; ANIMALS; BRAIN; HUMANS; IMMUNE SYSTEM; MICE; STROKE; T-LYMPHOCYTES; TIME FACTORS;

EID: 80051980871     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1107368108     Document Type: Article

References (46)

1. Donnan G.A., Fisher M., Macleod M., Davis S.M. (2008) Stroke. Lancet 371:1612-1623. (Pubitemid 351626845)
2. Lees K.R., et al.; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group (2010) Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375:1695-1703.
3. Lansberg M.G., Bluhmki E., Thijs V.N. (2009) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: A metaanalysis. Stroke 40:2438-2441.
4. Lo E.H., Dalkara T., Moskowitz M.A. (2003) Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415. (Pubitemid 37280178)
5. Hossmann K.A. (2006) Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 26:1057-1083.
6. Liesz A., et al. (2009) Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 15:192-199.
7. Shichita T., et al. (2009) Pivotal role of cerebral interleukin-17- producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 15:946-950.
8. Moskowitz M.A., Lo E.H., Iadecola C. (2010) The science of stroke: Mechanisms in search of treatments. Neuron 67:181-198.
9. Chabas D., et al. (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735. (Pubitemid 33104847)
10. Li D.W., et al. (2005) Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation. Mol Biol Cell 16:4437-4453. (Pubitemid 41262909)
11. Ousman S.S., et al. (2007) Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 448:474-479. (Pubitemid 47123511)
12. Van Noort J.M., et al. (1995) The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature 375:798-801.
13. Pangratz-Fuehrer S., Kaur K., Ousman S.S., Steinman L., Liao Y.J. (2011) Functional rescue of experimental ischemic optic neuropathy with alphaB-crystallin. Eye (Lond) 25:809-817.
14. Doyle K.P., et al. (2008) Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab 28:1235-1248. (Pubitemid 351733347)
15. Encarnacion A., et al. (2011) Long-term behavioral assessment of function in an experimental model for ischemic stroke. J Neurosci Methods 196:247-257.
16. Gelderblom M., et al. (2009) Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 40:1849-1857.
17. Becker K., Kindrick D., McCarron R., Hallenbeck J., Winn R. (2003) Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: A role for lymphocytes in ischemic brain injury? Stroke 34:1809-1815. (Pubitemid 36842650)
18. Zhang Z., et al. (2009) Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine 46:79-91.
19. Liang S.C., et al. (2007) An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 179:7791-7799.
20. Smith E., et al. (2007) IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice. J Immunol 179:8274-8279.
21. Liesz A., et al. (2009) The spectrum of systemic immune alterations after murine focal ischemia: Immunodepression versus immunomodulation. Stroke 40:2849-2858.
22. Hug A., et al. (2009) Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 40:3226-3232.
23. Urra X., et al. (2009) Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab 29:994-1002.
24. Kamradt M.C., Chen F., Cryns V.L. (2001) The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 276:16059-16063.
25. Kamradt M.C., Chen F., Sam S., Cryns V.L. (2002) The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation. J Biol Chem 277:38731-38736. (Pubitemid 35154735)
26. Kamradt M.C., et al. (2005) The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280:11059-11066. (Pubitemid 40418409)
27. Minami M., Mizutani T., Kawanishi R., Suzuki Y., Mori H. (2003) Neuronal expression of alphaB crystallin in cerebral infarction. Acta Neuropathol 105:549-554. (Pubitemid 36798854)
28. Piao C.S., Kim S.W., Kim J.B., Lee J.K. (2005) Co-induction of alphaB-crystallin and MAP-KAPK-2 in astrocytes in the penumbra after transient focal cerebral ischemia. Exp Brain Res 163:421-429.
29. Imura T., et al. (1999) Differential expression of small heat shock proteins in reactive astrocytes after focal ischemia: Possible role of beta-adrenergic receptor. J Neurosci 19:9768-9779. (Pubitemid 30226650)
30. Glickman S.W., Phillips S., Anstrom K.J., Laskowitz D.T., Cairns C.B. (2010) Discriminative capacity of biomarkers for acute stroke in the emergency department. J Emerg Med, 10.1016/j.jemermed.2010.02.025.
31. Sreekumar P.G., et al. (2010) αB crystallin is apically secreted within exosomes by polarized human retinal pigment epithelium and provides neuroprotection to adjacent cells. PLoS ONE 5:e12578.
32. Lindgren A., Lindoff C., Norrving B., Astedt B., Johansson B.B. (1996) Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 27:1066-1071. (Pubitemid 26177608)
33. Brown R.D., Whisnant J.P., Sicks J.D., O'Fallon W.M., Wiebers D.O. (1996) Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989. Stroke 27:373-380. (Pubitemid 26081427)
34. Liu F., Yuan R., Benashski S.E., McCullough L.D. (2009) Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab 29:792-802.
35. Ransohoff R.M. (2007) Inflammatory disease: Assault on the guardian. Nature 448:421-422.
36. Gesuete R., et al. (2009) Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol 66:332-342.
37. Macrez R., et al. (2011) Stroke and the immune system: From pathophysiology to new therapeutic strategies. Lancet Neurol 10:471-480.
38. Mulcahy N.J., Ross J., Rothwell N.J., Loddick S.A. (2003) Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 140:471-476. (Pubitemid 37330491)
39. Wei Y., et al. (2011) Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 69:119-129.
40. Liesz A., et al. (2011) Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 134:704-720.
41. Takeda H., et al. (2002) Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 33:2156-2163. (Pubitemid 35014621)
42. Yrjänheikki J., et al. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496-13500.
43. Clarkson A.N., Huang B.S., Macisaac S.E., Mody I., Carmichael S.T. (2010) Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 468:305-309.
44. Bhat R., et al. (2010) Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci USA 107:2580-2585.
45. Lo E.H. (2008) A new penumbra: Transitioning from injury into repair after stroke. Nat Med 14:497-500.
46. Lo E.H. (2010) Degeneration and repair in central nervous system disease. Nat Med 16:1205-1209.